Ipca Laboratories (IPCALAB) Hisse Özeti
Bir ilaç şirketi olan Ipca Laboratories Limited, Hindistan, Avrupa, Afrika, Amerika, Asya, BDT ve Avustralasya'da çeşitli terapötik segmentler için formülasyonlar ve aktif farmasötik bileşenler (API'ler) üretmekte ve pazarlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 3/6 |
IPCALAB Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ipca Laboratories Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | ₹1,789.00 |
| 52 Haftanın En Yüksek Seviyesi | ₹1,944.90 |
| 52 Haftanın En Düşük Seviyesi | ₹1,251.60 |
| Beta | 0.049 |
| 1 Aylık Değişim | 10.55% |
| 3 Aylık Değişim | 16.01% |
| 1 Yıllık Değişim | 20.19% |
| 3 Yıllık Değişim | 98.25% |
| 5 Yıllık Değişim | 70.74% |
| Halka arzdan bu yana değişim | 4,607.89% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 17
IPCALAB: Board Reviews And Merger Plan Will Shape Measured Upside Potential
The analyst price target for Ipca Laboratories has shifted from ₹1,887 to about ₹1,968, with analysts linking this change to updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Ipca Laboratories has scheduled a board meeting on May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a dividend recommendation for the 2025-26 financial year.
Anlatı Güncellemesi • Jul 03
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.Recent updates
Anlatı Güncellemesi • Jul 17
IPCALAB: Board Reviews And Merger Plan Will Shape Measured Upside Potential
The analyst price target for Ipca Laboratories has shifted from ₹1,887 to about ₹1,968, with analysts linking this change to updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Ipca Laboratories has scheduled a board meeting on May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a dividend recommendation for the 2025-26 financial year.Anlatı Güncellemesi • Jul 03
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.
Anlatı Güncellemesi • Jun 19
IPCALAB: Upcoming Board Results And Dividend Move Will Reinforce Bullish View
Analysts have lifted their price target for Ipca Laboratories stock to ₹1,720 from ₹1,655, reflecting updated assumptions that combine slightly different views on revenue growth, profit margins and future P/E levels. What’s in the News for Ipca Laboratories A board meeting of Ipca Laboratories is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.Anlatı Güncellemesi • Jun 04
IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential
Analysts now set a higher fair value price target for Ipca Laboratories at ₹1,887, compared with ₹1,731 earlier, reflecting updated assumptions on revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.Analiz Makalesi • Jun 03
Should You Be Adding Ipca Laboratories (NSE:IPCALAB) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Anlatı Güncellemesi • May 06
IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility
Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).Anlatı Güncellemesi • Apr 19
IPCALAB: Upcoming Results And Revised Assumptions Will Guide Earnings Visibility
Analysts have trimmed their fair value estimate for Ipca Laboratories slightly from about ₹1,416 to around ₹1,407, reflecting updated assumptions on future revenue growth, profit margins and a modestly lower future P/E multiple. What's in the News Board meeting scheduled on February 13, 2026, to consider and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Anlatı Güncellemesi • Apr 05
IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value
Analysts have kept their fair value estimate for Ipca Laboratories steady at ₹1,655, reflecting unchanged assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for February 13, 2026 to consider and record the standalone unaudited financial results for the third quarter ended December 31, 2025 (Key Developments).Anlatı Güncellemesi • Mar 22
IPCALAB: Upcoming Results Review And Margins Outlook Will Support Steady Fair Value
Analysts now set their fair value estimate for Ipca Laboratories at about ₹1,655, up from roughly ₹1,634. This reflects updated assumptions that include a slightly higher profit margin and P/E multiple, along with modest adjustments to projected revenue growth and an unchanged discount rate.Anlatı Güncellemesi • Mar 07
IPCALAB: Upcoming Results And Revised Assumptions Will Shape Future Earnings Visibility
Analysts have raised their fair value estimate for Ipca Laboratories from ₹1,106 to about ₹1,416, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E that they consider to more accurately capture the company’s earnings potential. What's in the News A board meeting is scheduled for February 13, 2026, to review and take on record the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (Key Developments).Anlatı Güncellemesi • Feb 20
IPCALAB: Upcoming Board Results Review Will Support Upbeat Long Term Outlook
Analysts have nudged their fair value estimate for Ipca Laboratories up from about ₹1,565 to roughly ₹1,634, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board meeting scheduled for February 13, 2026, to review and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025.Analiz Makalesi • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...Analiz Makalesi • Feb 12
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Anlatı Güncellemesi • Feb 06
IPCALAB: Upcoming Results Review Will Support Measured Outlook And Modest Assumption Shifts
Analysts have nudged their price target for Ipca Laboratories slightly higher, citing modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and record standalone unaudited financial results for the third quarter ended December 31, 2025.Anlatı Güncellemesi • Jan 23
IPCALAB: Firmer Margins And Tighter P E Will Support Future Upside Potential
Analysts have inched up their fair value estimate for Ipca Laboratories to ₹1,731 per share from ₹1,730 per share, citing updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple in their models. What's in the News Board meeting scheduled for February 13, 2026, to consider and record standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Analiz Makalesi • Jan 21
Ipca Laboratories Limited's (NSE:IPCALAB) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 45.1x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Anlatı Güncellemesi • Jan 08
IPCALAB: Board Meeting Schedule And Stable Assumptions Will Shape Balanced Outlook
Analysts have slightly raised their price target on Ipca Laboratories to ₹1,555 from ₹1,552, citing small adjustments to long term assumptions on revenue growth, profit margin and future P/E multiples. What's in the News Board meeting scheduled on Oct 17, 2025, at 17:00 Indian Standard Time (company filing) Board meeting set for Nov 13, 2025, to consider and record Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended Sep 30, 2025 (company filing) Valuation Changes Fair Value: The analyst fair value estimate has moved marginally higher from ₹1,551.82 to ₹1,555.06 per share.Anlatı Güncellemesi • Dec 24
IPCALAB: Improved Margins And Lower Multiple Will Support Future Upside Potential
Analysts have trimmed their price target on Ipca Laboratories by approximately ₹80 to around ₹1,730, reflecting slightly softer revenue growth assumptions, while still factoring in improved profit margins and a lower future P/E multiple. What's in the News Board meeting scheduled on October 17, 2025, at 17:00 IST to discuss corporate matters and ongoing strategic priorities (company filing).Anlatı Güncellemesi • Dec 10
IPCALAB: Biosimilar Partnership And Board Meetings Will Shape Balanced Outlook
Analysts have nudged their price target for Ipca Laboratories slightly higher to approximately ₹1,552 from about ₹1,543, reflecting modestly improved valuation multiples, even though there were only minor trims to long term revenue growth and profit margin assumptions. What's in the News Ipca Laboratories and BioSimilar Sciences PR LLC entered a Technology Transfer and Joint Development Agreement to shift late stage development, clinical manufacturing, and commercial supply of a next generation anti cancer or anti inflammatory monoclonal antibody biosimilar to BSS sterile campus in Aguadilla, Puerto Rico (company announcement) A board meeting is scheduled on October 17, 2025, at 17:00 Indian Standard Time to review corporate matters (company filing) A board meeting is set for November 13, 2025, to consider and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value Estimate has risen slightly from around ₹1,543 to about ₹1,552, reflecting a modestly higher intrinsic value.Analiz Makalesi • Dec 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Anlatı Güncellemesi • Nov 26
IPCALAB: Technology Partnership and Upcoming Board Meetings Will Influence Outlook
Narrative Update on Ipca Laboratories Analysts have raised their price target for Ipca Laboratories from ₹1,529.94 to ₹1,542.56. This change reflects optimism due to improved forecasts for revenue growth and profit margins.Anlatı Güncellemesi • Nov 11
IPCALAB: Technology Agreement With BioSimilar Sciences Will Drive Future Expansion
Analysts have raised their price target for Ipca Laboratories from ₹1,501.41 to ₹1,529.94, citing updated model assumptions and slight adjustments to long-term growth and margin forecasts. What's in the News Ipca Laboratories held a Board Meeting on October 17, 2025, at 17:00 Indian Standard Time.Analiz Makalesi • Oct 19
Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Ipca...Analiz Makalesi • Sep 05
If EPS Growth Is Important To You, Ipca Laboratories (NSE:IPCALAB) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analiz Makalesi • Aug 15
The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
NSEI:IPCALAB 1 Year Share Price vs Fair Value Explore Ipca Laboratories's Fair Values from the Community and select...Analiz Makalesi • Jul 08
Ipca Laboratories (NSE:IPCALAB) Will Pay A Dividend Of ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...Analiz Makalesi • Jun 24
Ipca Laboratories' (NSE:IPCALAB) Dividend Will Be ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...Analiz Makalesi • Jun 01
Ipca Laboratories Limited Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Ipca Laboratories Limited ( NSE:IPCALAB ) released its yearly result to the market...Analiz Makalesi • May 22
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 51.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Analiz Makalesi • Feb 16
Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders might have noticed that Ipca Laboratories Limited ( NSE:IPCALAB ) filed its third-quarter result this time...Analiz Makalesi • Jan 10
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Dec 20
Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
With a price-to-earnings (or "P/E") ratio of 61.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...
Yeni Anlatı • Dec 12
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.Analiz Makalesi • Nov 17
Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
The board of Ipca Laboratories Limited ( NSE:IPCALAB ) has announced that it will pay a dividend of ₹2.00 per share on...Analiz Makalesi • Sep 10
Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Ipca Laboratories Limited's ( NSE:IPCALAB ) price-to-earnings (or "P/E") ratio of 61.7x might make it look like a...Analiz Makalesi • Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Ipca Laboratories Limited ( NSE:IPCALAB ) recently...Analiz Makalesi • May 24
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 31x, you may consider Ipca...Analiz Makalesi • Feb 07
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
With a price-to-earnings (or "P/E") ratio of 61.8x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Analiz Makalesi • Jan 09
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Aug 20
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Feb 28
Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Hissedar Getirileri
| IPCALAB | IN Pharmaceuticals | IN Pazar | |
|---|---|---|---|
| 7D | -0.6% | -0.7% | -0.7% |
| 1Y | 20.2% | 11.8% | 1.7% |
Getiri vs. Endüstri: IPCALAB geçen yıl % 11.8 oranında getiri sağlayan Indian Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: IPCALAB geçen yıl % 1.7 oranında getiri sağlayan Indian Piyasasını aştı.
Fiyat Oynaklığı
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
İstikrarlı Hisse Senedi Fiyatı: IPCALAB son 3 ayda Indian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: IPCALAB 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1949 | 17,210 | Pranay Godha | www.ipca.com |
Bir ilaç şirketi olan Ipca Laboratories Limited, Hindistan, Avrupa, Afrika, Amerika, Asya, BDT ve Avustralasya'da çeşitli terapötik segmentler için formülasyonlar ve aktif farmasötik bileşenler (API'ler) üretmekte ve pazarlamaktadır. Anti-hipertansif, anti-sıtma, diüretik, DMARD ve antelmintik terapötik alanlarda API'ler sunmaktadır. Şirket ayrıca alerji, anti-neoplastik / kanser ilaçları, anti-artritik, anti-epileptik, anti-hipertansif, kardiyoloji, diyabet, dermatoloji, diyabetoloji, yumuşatıcılar / koruyucular, ateş, gastroenteroloji dahil olmak üzere terapötik segmentlerde jenerik ve markalı formülasyonlar sunmaktadır, Hematoloji, helmintikler, hepatoprotektifler, immünosupresan, enfeksiyon hastalıkları, sıtma, nöroloji, nöropatik ağrı ve NSAID'lerin yanı sıra nutrasötikler, oftalmoloji, oral anti diyabet ilacı, ortopedi, probiyotikler, psikiyatri, solunum, romatoloji ve üroloji.
Ipca Laboratories Limited Temel Bilgiler Özeti
| IPCALAB temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | ₹450.98b |
| Kazançlar(TTM) | ₹11.41b |
| Gelir(TTM) | ₹96.47b |
39.8x
F/K Oranı4.7x
P/S OranıIPCALAB aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| IPCALAB gelir tablosu (TTM) | |
|---|---|
| Gelir | ₹96.47b |
| Gelir Maliyeti | ₹31.62b |
| Brüt Kâr | ₹64.86b |
| Diğer Giderler | ₹53.44b |
| Kazançlar | ₹11.41b |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 13, 2026
| Hisse başına kazanç (EPS) | 44.98 |
| Brüt Marj | 67.23% |
| Net Kâr Marjı | 11.83% |
| Borç/Özkaynak Oranı | 7.4% |
IPCALAB uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.3%
Mevcut Temettü Verimi13%
Ödeme OranıIPCALAB güvenilir bir temettü ödüyor mu?
IPCALAB temettü geçmişine ve kıyaslamalara bakın| Ipca Laboratories temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Aug 07 2026 |
| Temettü Ödeme Tarihi | Sep 10 2026 |
| Eski temettüye kadar geçen günler | 9 days |
| Temettü ödeme tarihine kadar geçen günler | 43 days |
IPCALAB güvenilir bir temettü ödüyor mu?
IPCALAB temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/28 16:06 |
| Gün Sonu Hisse Fiyatı | 2026/07/28 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Ipca Laboratories Limited 38 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |